Primer Capital invested 11 million in the treatment of thrombosis

Primer Capital Fund invested 11 million rubles in the company "FC Laboratories", which is developing a drug for the treatment and prevention of thrombosis.

Thrombosis is the formation of solid blood clots (blood clots) in blood vessels. Circulatory disorders are always a danger, as a result of which the patency of blood vessels may decrease, which leads to severe conditions. The greatest danger is a sudden detachment of a blood clot, which can get into the heart and then into the lungs or brain. Today, about 40% of deaths among adults are associated with the pathology of thrombosis.

At the moment , several types of drugs are used to treat thrombosis:

• indirect anticoagulants (requiring constant monitoring of blood clotting),
• indirect thrombin inhibitors (whose pharmacokinetics depend on the individual characteristics of the patient, his diet and other therapy),
• direct thrombin inhibitors (characterized by a minimal risk of bleeding and other side effects, which makes them the most modern class of drugs for the treatment of thrombosis).

The market for direct thrombin inhibitors is highly competitive, and at the moment Russian drugs are not represented on it. The drug "FC Laboratories" represents a new structure of a highly specific direct thrombin inhibitor. Its expected pharmacological properties meet international standards and allow it to compete with existing drugs that are presented on the EAEU market. The drug was developed using a combination of computer modeling and chemical synthesis methods, which is a modern and generally accepted approach in the pharmaceutical industry.

Elizaveta Rozhdestvenskaya, Executive Director of Primer Capital:
"Being a representative of a group of direct inhibitors, the drug under development has several key advantages: oral administration, no toxicity, high specificity. Given the fact that this is the first Russian drug of this class, we expect that it will be more affordable and will make the treatment of thrombosis comfortable and less painful for each patient."

The investments of Primer Capital together with a grant of the Ministry of Education of the Russian Federation in the amount of 33 million rubles will be used as part of preclinical studies of the drug.

Portal "Eternal youth" http://vechnayamolodost.ru  07.12.2016